CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Sulbactam

舒巴坦酸 杂质对照品Sulbactam Impurities

EP21 个杂质条目21 impurity entries

本页汇总 舒巴坦酸 的 21 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 21 impurity reference standards of Sulbactam with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 舒巴坦酸(Sulbactam)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSulbactam: alkaline degradation and determination by high-performance liquid chromatography
    Chemical & pharmaceutical bulletin · 1984 · Haginaka J et al.  ·  PMID 6094028  ·  DOI
  2. 杂质研究Impurity studiesHigh-performance liquid chromatographic assay of sulbactam using pre-column reaction with 1,2,4-triazole
    Journal of chromatography · 1985 · Haginaka J et al.  ·  PMID 2991310  ·  DOI
  3. 分析方法Analytical MethodsDevelopment and Validation of UPLC Tandem Mass Spectrometry Assay for Ceftibuten and Sulbactam in Human Plasma
    Journal of chromatographic science · 2024 · Valero-Rivera KP et al.  ·  PMID 38521966  ·  DOI
  4. 分析方法Analytical MethodsDevelopment of green micellar HPLC-DAD method for simultaneous determination of some sulbactam combinations used in COVID-19 regimen
    BMC chemistry · 2023 · Ragab GH et al.  ·  PMID 37543613  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisAn efficient method for the synthesis of sulbactam pivoxil
    Farmaco (Societa chimica italiana : 1989) · 2000 · Changov LS et al.  ·  PMID 10782385  ·  DOI

舒巴坦酸 —— 原料药与杂质对照品Sulbactam — drug substance & impurities

共 21 个条目(含原料药本体)21 items incl. the drug substance
Sulbactam Impurity 1 (Sulbactam EP Impurity A) structure
EPA
舒巴坦酸杂质1 (舒巴坦酸EP杂质A)Sulbactam Impurity 1 (Sulbactam EP Impurity A)
Sulbactam Impurity 1 (Sulbactam EP Impurity A)
CAS No.23315-18-6
Chemical FormulaC5H11NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 3(Sulbactam EP Impurity C) structure
EPC
舒巴坦酸杂质3(舒巴坦酸EP杂质C)Sulbactam Impurity 3(Sulbactam EP Impurity C)
Sulbactam Impurity 3(Sulbactam EP Impurity C)
CAS No.75527-87-6
Chemical FormulaC8H10BrNO5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 4 Monomer(Sulbactam EP Impurity D ) structure
EPD
舒巴坦酸杂质4单体(舒巴坦酸EP杂质D)Sulbactam Impurity 4 Monomer(Sulbactam EP Impurity D )
Sulbactam Impurity 4 Monomer(Sulbactam EP Impurity D )
CAS No.26631-90-3
Chemical FormulaC8H10BrNO3S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 4 Potassium Salt(Sulbactam EP Impurity D Potassium Salt) structure
EPD
舒巴坦酸杂质4 钾盐(舒巴坦酸EP杂质D 钾盐)Sulbactam Impurity 4 Potassium Salt(Sulbactam EP Impurity D Potassium Salt)
Sulbactam Impurity 4 Potassium Salt(Sulbactam EP Impurity D Potassium Salt)
CAS No.4027-64-9
Chemical FormulaC8H9BrKNO3S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 4(Sulbactam EP Impurity D Sodium Salt) structure
EPD
舒巴坦酸杂质4(舒巴坦酸EP杂质D钠盐)Sulbactam Impurity 4(Sulbactam EP Impurity D Sodium Salt)
Sulbactam Impurity 4(Sulbactam EP Impurity D Sodium Salt)
CAS No.73335-78-1
Chemical FormulaC8H9BrNNaO3S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 5(Sulbactam EP Impurity E) structure
EPE
舒巴坦酸杂质5(舒巴坦酸EP杂质E)Sulbactam Impurity 5(Sulbactam EP Impurity E)
Sulbactam Impurity 5(Sulbactam EP Impurity E)
CAS No.76646-91-8
Chemical FormulaC8H9Br2NO5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 6(Sulbactam EP Impurity F) structure
EPF
舒巴坦酸杂质6(舒巴坦酸EP杂质F)Sulbactam Impurity 6(Sulbactam EP Impurity F)
Sulbactam Impurity 6(Sulbactam EP Impurity F)
CAS No.24158-88-1
Chemical FormulaC8H9Br2NO3S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Monomer-d5 structure
—
舒巴坦酸单体-d5Sulbactam Monomer-d5
Sulbactam Monomer-d5
CAS No.2734928-80-2
Chemical FormulaC8H6D5NO5S
Purity>95%询价On request
Sulbactam Monomer-d2 structure
—
舒巴坦酸单体-d2Sulbactam Monomer-d2
Sulbactam Monomer-d2
CAS No.77741-83-4
Chemical FormulaC8H9D2NO5S
Purity>95%询价On request
Sulbactam Impurity 8 structure
8
舒巴坦酸杂质8Sulbactam Impurity 8
Sulbactam Impurity 8
CAS No.36091-15-3
Chemical FormulaC8H12N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 9 Sodium Salt structure
9
舒巴坦酸杂质9钠盐Sulbactam Impurity 9 Sodium Salt
Sulbactam Impurity 9 Sodium Salt
CAS No.4027-62-7
Chemical FormulaC8H10NNaO3S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 9 structure
9
舒巴坦酸杂质9Sulbactam Impurity 9
Sulbactam Impurity 9
CAS No.4027-63-8
Chemical FormulaC8H10KNO3S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 10 structure
10
舒巴坦酸杂质10Sulbactam Impurity 10
Sulbactam Impurity 10
CAS No.75527-88-7
Chemical FormulaC8H10BrNO5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 11 structure
11
舒巴坦酸杂质11Sulbactam Impurity 11
Sulbactam Impurity 11
CAS No.79703-02-9
Chemical FormulaC8H10BrNO4S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 13 structure
13
舒巴坦酸杂质13Sulbactam Impurity 13
Sulbactam Impurity 13
CAS No.128657-18-1
Chemical FormulaC8H9Br2NO4S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 14 structure
14
舒巴坦酸杂质14Sulbactam Impurity 14
Sulbactam Impurity 14
CAS No.4888-97-5
Chemical FormulaC8H12N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 16 structure
16
舒巴坦酸杂质16Sulbactam Impurity 16
Sulbactam Impurity 16
CAS No.76247-39-7
Chemical FormulaC9H12INO5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 21 structure
21
舒巴坦酸杂质21Sulbactam Impurity 21
Sulbactam Impurity 21
CAS No.69388-79-0
Chemical FormulaC14H21NO7S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 24 structure
24
舒巴坦酸杂质24Sulbactam Impurity 24
Sulbactam Impurity 24
CAS No.3053-85-8
Chemical FormulaC9H12N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 41 (Mixture of Enantiomers) structure
41
舒巴坦酸杂质41 (对映异构体混合物)Sulbactam Impurity 41 (Mixture of Enantiomers)
Sulbactam Impurity 41 (Mixture of Enantiomers)
CAS No.774495-96-4
Chemical FormulaC8H11NO5S
Purity>95%询价On request
10mg25mg50mg100mg
Sulbactam Impurity 41-d5 (Mixture of Enantiomers) structure
41-D5
舒巴坦酸杂质41-d5 (对映异构体混合物)Sulbactam Impurity 41-d5 (Mixture of Enantiomers)
Sulbactam Impurity 41-d5 (Mixture of Enantiomers)
CAS No.1322880-00-1
Chemical FormulaC8H6D5NO5S
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

舒巴坦酸 —— 研究文献与合成路线Sulbactam — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 舒巴坦酸 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Sulbactam. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Sulbactam: alkaline degradation and determination by high-performance liquid chromatography
    Haginaka J, Yasuda H, Uno T, et al. · Chemical & pharmaceutical bulletin · 1984 · 被引 11cited 11
  2. CE versus LC for simultaneous determination of amoxicillin/clavulanic acid and ampicillin/sulbactam in pharmaceutical formulations for injections
    Pajchel G, Pawłowski K, Tyski S · Journal of pharmaceutical and biomedical analysis · 2002 · 被引 40cited 40
  3. Simultaneous determination of ampicillin, cefoperazone, and sulbactam in pharmaceutical formulations by HPLC with beta-cyclodextrin stationary phase
    Tsou TL, Huang YC, Lee CW, et al. · Journal of separation science · 2007 · 被引 16cited 16
  4. Ultraviolet spectrophotometry (dual wavelength and chemometric) and high performance liquid chromatography for simultaneous estimation of meropenem and sulbactam sodium in pharmaceutical dosage form
    Marwada KR, Patel JB, Patel NS, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2014 · 被引 9cited 9
  5. High-performance liquid chromatographic assay of sulbactam using pre-column reaction with 1,2,4-triazole
    Haginaka J, Wakai J, Yasuda H, et al. · Journal of chromatography · 1985 · 被引 12cited 12
  6. UV spectrophotometric simultaneous determination of cefoperazone and sulbactam in pharmaceutical formulations by derivative, Fourier and wavelet transforms
    Hoang VD, Loan NT, Tho VT, et al. · Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2014 · 被引 8cited 8

合成与制备工艺专利Synthesis & process patents

  1. Preparation method of sulbactam
    WANG ZHENGPING LIU · 公开号 CN1786002CN1786002 · 2006
  2. Preparation of cefoperazone and sulbactam sodium mixed powder
    YONGJIN WANG, HAISHENG DU, HONGMEI XU · 公开号 CN101297809CN101297809 · 2008
  3. Stable cefoperazone sulbactam medicine compound preparation
    TAN SHENGLIAN FU · 公开号 CN101036654CN101036654 · 2007
  4. Sulbactam sodium bacteriophage complex and the preparing method thereof
    CAI HAIDE · 公开号 CN101062032CN101062032 · 2007
  5. Process for producing sulbactam valeryl oxygen methyl ester
    ZHENG WENYI HU · 公开号 CN1523026CN1523026 · 2004

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

舒巴坦酸 杂质谱研究要点Sulbactam — impurity profiling notes

下面这些是拿到 舒巴坦酸 的 21 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 21 impurity entries for Sulbactam, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances